Cargando…
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression
BACKGROUND: TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and Dc...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924860/ https://www.ncbi.nlm.nih.gov/pubmed/17592646 http://dx.doi.org/10.1186/1471-2407-7-108 |
_version_ | 1782134219850383360 |
---|---|
author | Vigneswaran, Nadarajah Baucum, Darryl C Wu, Jean Lou, Yahuan Bouquot, Jerry Muller, Susan Zacharias, Wolfgang |
author_facet | Vigneswaran, Nadarajah Baucum, Darryl C Wu, Jean Lou, Yahuan Bouquot, Jerry Muller, Susan Zacharias, Wolfgang |
author_sort | Vigneswaran, Nadarajah |
collection | PubMed |
description | BACKGROUND: TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2) receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa (NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC) in order to characterize the changes in their expression patterns during OSCC initiation and progression. METHODS: DNA microarray, immunoblotting and immunohistochemical analyses were used to examine the expression levels of TRAIL and its receptors in oral epithelial cell lines and in archival tissues of NOM, OPM, primary and metastatic OSCC. Apoptotic rates of tumor cells and tumor-infiltrating lymphocytes (TIL) in OSCC specimens were determined by cleaved caspase 3 immunohistochemistry. RESULTS: Normal oral epithelia constitutively expressed TRAIL, but expression was progressively lost in OPM and OSCC. Reduction in DcR2 expression levels was noted frequently in OPM and OSCC compared to respective patient-matched uninvolved oral mucosa. OSCC frequently expressed DR4, DR5 and DcR1 but less frequently DcR2. Expression levels of DR4, DR5 and DcR1 receptors were not significantly altered in OPM, primary OSCC and metastatic OSCC compared to patient-matched normal oral mucosa. Expression of proapoptotic TRAIL-receptors DR4 and DR5 in OSCC seemed to depend, at least in part, on whether or not these receptors were expressed in their parental oral epithelia. High DR5 expression in primary OSCC correlated significantly with larger tumor size. There was no significant association between TRAIL-R expression and OSSC histology grade, nodal status or apoptosis rates of tumor cells and TIL. CONCLUSION: Loss of TRAIL expression is an early event during oral carcinogenesis and may be involved in dysregulation of apoptosis and contribute to the molecular carcinogenesis of OSCC. Differential expressions of TRAIL receptors in OSCC do not appear to play a crucial role in their apoptotic rate or metastatic progression. |
format | Text |
id | pubmed-1924860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-19248602007-07-19 Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression Vigneswaran, Nadarajah Baucum, Darryl C Wu, Jean Lou, Yahuan Bouquot, Jerry Muller, Susan Zacharias, Wolfgang BMC Cancer Research Article BACKGROUND: TRAIL plays an important role in host immunosurveillance against tumor progression, as it induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2) receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa (NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC) in order to characterize the changes in their expression patterns during OSCC initiation and progression. METHODS: DNA microarray, immunoblotting and immunohistochemical analyses were used to examine the expression levels of TRAIL and its receptors in oral epithelial cell lines and in archival tissues of NOM, OPM, primary and metastatic OSCC. Apoptotic rates of tumor cells and tumor-infiltrating lymphocytes (TIL) in OSCC specimens were determined by cleaved caspase 3 immunohistochemistry. RESULTS: Normal oral epithelia constitutively expressed TRAIL, but expression was progressively lost in OPM and OSCC. Reduction in DcR2 expression levels was noted frequently in OPM and OSCC compared to respective patient-matched uninvolved oral mucosa. OSCC frequently expressed DR4, DR5 and DcR1 but less frequently DcR2. Expression levels of DR4, DR5 and DcR1 receptors were not significantly altered in OPM, primary OSCC and metastatic OSCC compared to patient-matched normal oral mucosa. Expression of proapoptotic TRAIL-receptors DR4 and DR5 in OSCC seemed to depend, at least in part, on whether or not these receptors were expressed in their parental oral epithelia. High DR5 expression in primary OSCC correlated significantly with larger tumor size. There was no significant association between TRAIL-R expression and OSSC histology grade, nodal status or apoptosis rates of tumor cells and TIL. CONCLUSION: Loss of TRAIL expression is an early event during oral carcinogenesis and may be involved in dysregulation of apoptosis and contribute to the molecular carcinogenesis of OSCC. Differential expressions of TRAIL receptors in OSCC do not appear to play a crucial role in their apoptotic rate or metastatic progression. BioMed Central 2007-06-25 /pmc/articles/PMC1924860/ /pubmed/17592646 http://dx.doi.org/10.1186/1471-2407-7-108 Text en Copyright © 2007 Vigneswaran et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Vigneswaran, Nadarajah Baucum, Darryl C Wu, Jean Lou, Yahuan Bouquot, Jerry Muller, Susan Zacharias, Wolfgang Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
title | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
title_full | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
title_fullStr | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
title_full_unstemmed | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
title_short | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
title_sort | repression of tumor necrosis factor-related apoptosis-inducing ligand (trail) but not its receptors during oral cancer progression |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924860/ https://www.ncbi.nlm.nih.gov/pubmed/17592646 http://dx.doi.org/10.1186/1471-2407-7-108 |
work_keys_str_mv | AT vigneswarannadarajah repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression AT baucumdarrylc repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression AT wujean repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression AT louyahuan repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression AT bouquotjerry repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression AT mullersusan repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression AT zachariaswolfgang repressionoftumornecrosisfactorrelatedapoptosisinducingligandtrailbutnotitsreceptorsduringoralcancerprogression |